|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalRegion
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:ATCCode
|
L01XX72
|
|
gptkbp:brand
|
gptkb:Lumakras
gptkb:Lumykras
|
|
gptkbp:CASNumber
|
2296729-00-3
|
|
gptkbp:chemicalFormula
|
C30H30F2N6O3
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:contraindication
|
hypersensitivity to sotorasib
|
|
gptkbp:EMA_approval_date
|
2022-01-13
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:FDAApproved
|
2021-05-28
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:genericName
|
gptkb:sotorasib
|
|
gptkbp:halfLife
|
5 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lumykras
|
|
gptkbp:indication
|
gptkb:non-small_cell_lung_cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Amgen
|
|
gptkbp:mechanismOfAction
|
KRAS G12C inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionRequired
|
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf
|
|
gptkbp:PubChem_CID
|
gptkb:DB16335
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
fatigue
cough
elevated liver enzymes
hepatotoxicity
|
|
gptkbp:target
|
gptkb:KRAS_G12C_mutant_protein
|
|
gptkbp:usedFor
|
advanced or metastatic NSCLC with KRAS G12C mutation
|
|
gptkbp:bfsParent
|
gptkb:sotorasib
|
|
gptkbp:bfsLayer
|
6
|